CompletedPhase 4

Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo

Brazil334 participantsStarted 2021-11-22

Plain-language summary

The goal of this clinical trial is to assess the efficacy and safety of a combination of aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine and cyanocobalamin as adjuvant therapy for vertigo comparatively to ginger under a double-blind randomized study design.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * clinical kinetosis * female study subjects must agree in using contraceptives during study period * dated informed consent read, understood and undersigned Exclusion Criteria: * hypersensitivity to the drugs of the study * history of gallblader stones * history of gastric mucosa inflammation * arterial blood pressure \>145/100 mmHg * use of medication for kinetosis other than the study drugs

What they're measuring

motion sickness assessment questionnaire

Timeframe: 1 year

Trial details

NCT IDNCT05221892

SponsorFundação Educacional Serra dos Órgãos

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-31

View on ClinicalTrials.gov More Vertigo trials